Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21964077 | 0.93 | L3MBTL1 (0.42) | L3MBTL1MAPTGAAPOLBALDH1A1 | |
| SCHEMBL21964207 | 0.88 | L3MBTL1 (0.38) | L3MBTL1MAPTGAATHRBATM | |
| SCHEMBL21964180 | 0.82 | L3MBTL1 (0.42) | L3MBTL1MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL6110479 | 0.80 | L3MBTL1 (0.43) | L3MBTL1MAPTGAATHRBATM | |
| SCHEMBL22011478 | 0.80 | ALDH1A1 (0.43) | L3MBTL1MAPTHSD11B1ALDH1A1MEN1 | |
| SCHEMBL21964069 | 0.80 | POLB (0.36) | L3MBTL1MAPTHSD11B1POLBALDH1A1 | |
| SCHEMBL21964127 | 0.80 | L3MBTL1 (0.39) | L3MBTL1MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL28604432 | 0.79 | ALDH1A1 (0.40) | L3MBTL1MAPTHSD11B1ALDH1A1MEN1 | |
| SCHEMBL28919216 | 0.78 | HPGD (0.43) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24220778 | 0.78 | CA12 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3880679-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | The University Of Sheffield (GB) | 2021-09-22 | — | — | EP | disclosed |
| CN-113227091-A | As AM2Heterocyclic spiro-compounds as receptor inhibitors | 谢菲尔德大学 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020099882-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, AGTR1 | L3MBTL1 4019/4885MAPT 4581/4885HSD11B1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.